Drug dosing in continuous renal replacement therapy: general rules

被引:98
作者
Schetz, Miet [1 ]
机构
[1] Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium
关键词
acute kidney injury; continuous renal replacement therapy; drug elimination; pharmacodynamics; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; INTENSIVE-CARE-UNIT; HIGH-VOLUME HEMOFILTRATION; IN-VITRO; ANTIMICROBIAL THERAPY; PHARMACOKINETICS; MEROPENEM; FAILURE; ELIMINATION;
D O I
10.1097/MCC.0b013e3282f0a3d3
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose of review Continuous renal replacement therapy is increasingly used in the management of acute kidney injury in critically ill patients. The potential extracorporeal removal of drugs, in particular the removal of antimicrobials, is a concern to many clinicians. The results of clinical studies cannot be generalized because different treatment modalities and settings are used in heterogeneous patient populations. This review aims to provide general guidelines for drug dosing during continuous renal replacement therapy. Recent findings The basic principles underlying drug removal with different modalities of continuous renal replacement therapy are reviewed and general approaches for drug dosage adaptation are proposed. Dosing should consider extracorporeal clearance, mainly depending on the dose and mode of therapy, type of membrane and protein binding, but also fractional extracorporeal clearance, accounting for hepatic, metabolic and residual renal clearance. Of note, pharmacokinetic variables may be highly variable in the critically ill. Appropriate dosing of antimicrobials additionally requires the application of pharmacodynamic principles. For nontoxic antimicrobials, the clinician should prefer slight overdosing, while monitoring of plasma concentrations is crucial for drugs with a narrow therapeutic index. Summary Drug dosage adaptation during continuous renal replacement therapy can use several approaches, which all include a degree of unpredictability and thus require maximal reliance on drug monitoring.
引用
收藏
页码:645 / 651
页数:7
相关论文
共 54 条
[11]   Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis [J].
Clark, WR ;
Hamburger, RJ ;
Lysaght, MJ .
KIDNEY INTERNATIONAL, 1999, 56 (06) :2005-2015
[12]   Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis [J].
Czock, David ;
Huesig-Linde, Cordula ;
Langhoff, Anita ;
Schoepke, Timo ;
Hafer, Carsten ;
de Groot, Kirsten ;
Swoboda, Stefanie ;
Kuse, Ernst ;
Haller, Hermann ;
Fliser, Danilo ;
Keller, Frieder ;
Kielstein, Jan T. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06) :1263-1268
[13]   Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis [J].
Fliser, D ;
Kielstein, JT .
NATURE CLINICAL PRACTICE NEPHROLOGY, 2006, 2 (01) :32-39
[14]   Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration [J].
Giles, LJ ;
Jennings, AC ;
Thomson, AH ;
Creed, G ;
Beale, RJ ;
McLuckie, A .
CRITICAL CARE MEDICINE, 2000, 28 (03) :632-637
[15]  
Golper TA, 1998, KIDNEY INT, V53, pS165
[16]  
GOLPER TA, 2001, CONTRIB NEPHROL, V93, P110
[17]   Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration [J].
Hirata, Kiyotaka ;
Aoyama, Takahiko ;
Matsumoto, Yoshiaki ;
Ogawa, Futosi ;
Yamazaki, Hiroshi ;
Kikuti, Arimichi ;
Yamamoto, Yasuhiro .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2007, 127 (05) :897-901
[18]   Meropenem and continuous renal replacement therapy:: In vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients [J].
Isla, A ;
Maynar, J ;
Sánchez-Izquierdo, JA ;
Gascón, AR ;
Arzuaga, A ;
Corral, E ;
Pedraz, JL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (11) :1294-1304
[19]   A COMPARISON OF MOLECULAR CLEARANCE RATES DURING CONTINUOUS HEMOFILTRATION AND HEMODIALYSIS WITH A NOVEL VOLUMETRIC CONTINUOUS RENAL REPLACEMENT SYSTEM [J].
JEFFREY, RF ;
KHAN, AA ;
PRABHU, P ;
TODD, N ;
GOUTCHER, E ;
WILL, EJ ;
DAVISON, AM .
ARTIFICIAL ORGANS, 1994, 18 (06) :425-428
[20]   Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis [J].
Joy, MS ;
Matzke, GR ;
Frye, RF ;
Palevsky, PM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (06) :1019-1027